Showing results (11-20 of 453) with videos related to

Sort By:
Pageof 46
Medicina Clinica|July 2, 2011
[Quantification of hepatitis B virus HBsAg: clinical implications]Maria Buti, Francisco Rodríguez Frías, Rafael Esteban
The Journal of Infectious Diseases|November 21, 2017
Tenofovir Alafenamide Fumarate: A New Tenofovir Prodrug for the Treatment of Chronic Hepatitis B InfectionMaria Buti, Mar Riveiro-Barciela, Rafael Esteban
Clinics in Liver Disease|May 16, 2026
Metabolic Dysfunction-Associated Steatotic Liver Disease and Viral HepatitisGeorge Papatheodoridis, Vasileios Lekakis, Rafael Esteban, et al.
Journal of Hepatology|December 20, 2005
Quality of life and cost-effectiveness of anti-HCV therapy in HIV-infected patientsMaria Buti, John Wong, Miguel Angel Casado, et al.
Pharmacoeconomics|October 21, 2005
Financial impact of two different ways of evaluating early virological response to peginterferon-alpha-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1Maria Buti, Miguel A Casado, Leslie Fosbrook, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 21, 2020
Optimal management of chronic hepatitis B patients receiving nucleos(t)ide analoguesMaria Buti, Luisa Roade, Mar Riveiro-Barciela, et al.
Therapeutic Advances in Infectious Disease|February 22, 2021
Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis BLuisa Roade, Mar Riveiro-Barciela, Rafael Esteban, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|February 8, 2006
Hepatitis B virus genome variability and disease progression: the impact of pre-core mutants and HBV genotypesMaria Buti, Francisco Rodriguez-Frias, Rosendo Jardi, et al.
International Urology and Nephrology|November 8, 2007
De novo nephrotic syndrome following pegylated interferon alfa 2b/ribavirin therapy for chronic hepatitis C infectionJose L Tovar, Maria Buti, Alfonso Segarra, et al.
Journal of Hepatology|July 7, 2009
Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis BMaria Buti, Max Brosa, Miguel A Casado, et al.
Pageof 46